13F Holdings
中文EN

CATX Perspective Therapeutics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 728387 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.2%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.8%
ROA-37.2%
ROIC (approx.)-44.1%
Asset turnover—

Leverage & solvency

Liabilities / assets19.4%
Debt / equity0.01x
Current ratio5.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20232022-12-31FY20222022-06-30
Income statement
Revenue——$1.43M$0$10.79M
Cost of revenue————$6.18M
Gross profit——$1.43M$0$0
R&D expense$84.22M$41.64M$21.31M$881,000$850,000
SG&A expense$30.23M$26.61M$21.06M$7.49M$5.57M
Operating income-$113.56M-$90.89M-$40.94M-$8.67M-$6.42M
Interest expense——$84,000$0$0
Pretax income-$104.43M-$80.43M-$40.11M-$8.05M-$6.30M
Income tax-$793,000-$2.10M-$2.65M$0$0
Net income-$103.12M-$79.28M-$46.51M-$10.76M-$7.27M
EBITDA-$110.31M-$88.58M-$39.95M-$8.40M-$6.17M
EPS (basic)-1.40-1.23-1.74-0.08-0.05
EPS (diluted)-1.40-1.23-1.74——
Weighted avg. shares (diluted)73.81M64.42M26.76M——
Balance sheet
Cash & equivalents$30.63M$61.58M$9.24M$20.99M$55.89M
Short-term investments$114.11M$165.34M$0$22.76M$0
Receivables$6,000$116,000$1.17M$1.36M$1.61M
Inventory———$1.41M$1.40M
Current assets$148.39M$231.16M$16.84M$53.22M$59.33M
PP&E, net$76.60M$57.32M$5.58M$371,000$1.98M
Goodwill—$0$24.06M$0—
Intangibles$362,000$279,000$354,000$25,000$107,000
Total assets$266.97M$341.10M$97.89M$58.09M$64.44M
Current liabilities$28.68M$18.23M$15.66M$3.12M$2.27M
Long-term debt$1.62M$1.68M$1.73M——
Total debt$1.62M$1.68M$1.73M——
Total liabilities$59.94M$50.43M$22.71M$3.45M$3.16M
Shareholders' equity$207.03M$290.67M$75.18M$54.64M$61.28M
Net debt-$29.00M-$59.90M-$7.51M——
Shares outstanding74.34M70.67M28.18M142.11M142.04M
Cash flow statement
Operating cash flow-$82.48M-$18.29M-$36.91M-$10.40M-$7.71M
Capital expenditure$12.75M$54.41M$1.07M$282,000$266,000
Free cash flow-$95.23M-$72.71M-$37.98M-$10.68M-$7.98M
Investing cash flow$41.23M-$218.93M$24.37M-$28.99M-$284,000
Financing cash flow$10.30M$289.38M$785,000$28,000$56,000
Depreciation & amortization$3.25M$2.31M$986,000$267,000$248,000
Stock-based compensation$8.97M$5.39M$3.74M$983,000$1.09M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.